Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huachansu combined with TD regimen for newly diagnosed multiple myeloma
ChiCTR-IPR-17013675Phase 4Completed
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cinobufacini, bortezomib, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Bone marrow plasma cells, Immunoglobulin level and 4 more. Started Dec 2016; status: completed.
02
Drugs
cinobufacinibortezomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-IPR-17013675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013675.